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Fibroblast growth factor (FGF) 21 is a marker associated with mitochondrial and cellular stress. Cardiac 
arrest causes mitochondrial stress, and we tested if FGF 21 would reflect the severity of hypoxia-
reperfusion injury after cardiac arrest. We measured serum concentrations of FGF 21 in 112 patients 
on ICU admission and 24, 48 and 72 h after out-of-hospital cardiac arrest with shockable initial 
rhythm included in the COMACARE study (NCT02698917). All patients received targeted temperature 
management for 24 h. We defined 6-month cerebral performance category 1–2 as good and 3–5 as 
poor neurological outcome. We used samples from 40 non-critically ill emergency room patients 
as controls. We assessed group differences with the Mann Whitney U test and temporal differences 
with linear modeling with restricted maximum likelihood estimation. We used multivariate logistic 
regression to assess the independent predictive value of FGF 21 concentration for neurologic outcome. 
The median (inter-quartile range, IQR) FGF 21 concentration was 0.25 (0.094–0.91) ng/ml in controls, 
0.79 (0.37–1.6) ng/ml in patients at ICU admission (P < 0.001 compared to controls) and peaked at 
48 h [1.2 (0.46–2.5) ng/ml]. We found no association between arterial blood oxygen partial pressure 
and FGF 21 concentrations. We observed with linear modeling an effect of sample timepoint (F 5.6, 
P < 0.01), poor neurological outcome (F 6.1, P = 0.01), and their interaction (F 3.0, P = 0.03), on FGF 21 
concentration. In multivariate logistic regression analysis, adjusting for relevant clinical covariates, 
higher average FGF 21 concentration during the first 72 h was independently associated with poor 
neurological outcome (odds ratio 1.60, 95% confidence interval 1.10–2.32). We conclude that post 
cardiac arrest patients experience cellular and mitochondrial stress, reflected as a systemic FGF 
21 response. This response is higher with a more severe hypoxic injury but it is not exacerbated by 
hyperoxia.
Abbreviations
FGF 21  Fibroblast growth factor 21
REML  Restricted maximum likelihood
Cardiac arrest causes great morbidity, mortality and economic  loss1. Neurological injury is the most common 
cause of death during post-resuscitation  care2 and less than half of those successfully resuscitated survive without 
neurological  sequelae3. The cessation of circulation during cardiac arrest causes ischaemia in tissues, disturbing 
normal cellular function and resulting in cell death. Reperfusion during cardiopulmonary resuscitation and after 
return of spontaneous circulation (ROSC) leads to generation of reactive oxygen species (ROS) and an inflam-
matory stress  response4. The brain is particularly vulnerable to the hypoxia-reperfusion injury in cardiac arrest 
due to its high metabolic activity and limited energy  reserves5, but also extracerebral organ failure complicates 
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 recovery6. Several markers of the magnitude of the hypoxia-reperfusion injury and associated inflammation after 
ROSC and their association with the severity of multiple organ failure have been  investigated7–9.
Fibroblast growth factor (FGF) 21, an endocrine hormone which may play a role in the development of 
reperfusion injury after cardiac arrest, is a member of the large FGF family. FGF 21 is derived mainly from the 
liver, and plays an important role in energy metabolism and  homeostasis10. Oxidative and inflammatory stress 
activate the integrated mitochondrial stress response leading to FGF 21 upregulation in the liver and the pan-
creas, but also in skeletal muscle and adipose  tissue11,12. Critical illness may cause mitochondrial dysfunction 
and, accordingly, elevated FGF 21 levels have been reported in intensive care  patients13. FGF 21 has been shown 
to ameliorate hypoxia-induced oxidative stress and inflammation in cerebral microvascular endothelial  cells14 
and to protect against myocardial ischaemia–reperfusion injury in a rat  model15. Accordingly, due to the pivotal 
role of mitochondria in oxidative metabolism and oxidative stress we tested the hypothesis that FGF 21 would 
reflect the severity of hypoxia-reperfusion injury after cardiac arrest. Based on previous reports from animal 
models of brain ischaemia indicating that hyperoxic reperfusion exacerbates mitochondrial  dysfunction16 and 
impairs long-term neurological  recovery17, we also asked, if post-arrest arterial blood oxygen partial pressure 
 (PaO2) has an impact on the FGF 21 response.
Methods
Study setting. This was an observational sub-study of the COMACARE study (NCT02698917). The proto-
col of the study has been reported  elsewhere18,19. Briefly, we included unconscious, mechanically ventilated adult 
(age between 18 and 80 years) Out-of-Hospital Cardiac Arrest (OHCA) patients admitted to the participating 
ICUs with ventricular fibrillation/tachycardia as initial rhythm and ROSC 10–45 min from the onset of cardiac 
arrest. All study patients received targeted temperature management of 33 or 36 °C for 24 h. COMACARE was a 
 23 factorial design study, where patients’ treatment targets were randomized to either normoxia  [PaO2 10–15 kPa 
(75–113 mmHg)] or moderate hyperoxia  [PaO2 20–25 kPa (150–225 mmHg)], and high or low normal arterial 
blood carbon dioxide partial pressure  (PaCO2) and mean arterial blood pressure (MAP). For the purposes of this 
study we analyzed data on the patients according to the  PaO2 target groups. The study protocol was approved by 
The Research Ethics Committee of the Northern Savo Hospital District (295/13.02.00/2015 §53). The study was 
conducted according to the Declaration of Helsinki. Deferred written informed consent was obtained from the 
next of kin and additionally from all those patients who regained sufficient neurological function for independ-
ent decision-making.
Laboratory analysis and control samples. We measured serum FGF 21 with a commercially available 
sandwich ELISA method (BioVendor Brno, Czech Republic). The detection limit reported by the manufacturer 
is 7 pg/ml and calibration range 30 pg/ml to 1,92 ng/ml. Intra-assay precision is reported as CV = 2.0% and inter-
assay precision as CV = 3.3%. We diluted samples as necessary to receive results within the calibration range. 
We measured serum FGF 21 concentration from samples collected on ICU admission and 24, 48 and 72 h after 
OHCA from 112 patients enrolled in the COMACARE-trial in the six participating Finnish ICUs. We used sam-
ples from 40 age- and gender-matched non-critically ill emergency room patients from the largest participating 
center as controls. This control group was not included in the COMACARE-trial. The controls were participants 
of another study (NCT03494790), where blood samples from patients with suspected infection were collected 
in an emergency department. The study protocol including FGF21 analysis was approved in the ethical board 
(HUS 1423/2017). The controls were chosen before FGF21 analysis and none of them was diagnosed as having 
had a severe infection.
Outcome. Cerebral Performance Category (CPC) at six months after the cardiac arrest, based on patient 
records and a telephone interview by an experienced neurologist blinded to the intervention groups, was used as 
the measure of neurological outcome. We defined 6-month CPC 1–2 as good and CPC 3–5 as poor neurological 
 outcome20.
Statistics. We assessed group differences with the Mann Whitney U test and Fisher’s exact test (continuous 
and categorial variables, respectively). Correlations between variables were assessed with Spearman’s rho. We 
calculated time-weighted mean  PaO2 values for timespans from admission to 24 h and from 24 to 48 h of ICU 
stay by first calculating the mean value for three-hour periods and second the mean of the three-hour means for 
a 24-h period. We did this to adjust for the altering frequency in blood gas analysis (for example, poor oxygena-
tion leading to increased frequency of sampling during the first hours of treatment).
We analyzed the association between neurological outcome and temporal change in FGF 21 and the asso-
ciation between  PaO2 intervention group and temporal change in FGF 21 using linear models with alternative 
covariance structures and restricted maximum likelihood (REML) estimation, a method well suited for analyzing 
longitudinal data with occasional missing  values21. The MIXED procedure of the SPSS program was used. We 
tested three potential covariance matrixes, namely, compound symmetry (CS), first order autoregressive (AR1) 
and unstructured (UN). We chose unstructured covariance matrix for the final analyses because it provided the 
lowest Akaike’s information criterion (AIC) in the presented models. We assessed significant effects and interac-
tions with least-significant-difference tests. The residuals followed a normal distribution on visual inspection in 
the models, confirming that the assumptions were reasonably met. We used P < 0.05 as threshold for significance 
for main effects and interactions and P < 0.0125 as threshold for significance for the four predefined pairwise 
comparisons of the interaction of sampling timepoint by outcome.
Finally, we tested the independent predictive value of FGF 21 for neurological outcome in logistic regression 
models adjusting for confounding variables. To reduce the dynamics of FGF 21 concentration to a single value 
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to be used in the logistic regression models, we calculated the average value of FGF 21 concentration from the 
available timepoints between admission and 72 h. We tested the following variables as potential confounders in 
univariate logistic regression: age, sex, body mass index (BMI), current smoker, bystander initiated resuscitation, 
time from collapse to the arrival of the first unit, time from collapse to ROSC, APACHE II score (excluding age), 
serum neuron specific enolase (NSE) measured 48 h after cardiac arrest. Variables with P < 0.3 in the univariate 
analyses (age, bystander initiated resuscitation, time to ROSC, APACHE II score excluding age and 48 h NSE) 
were selected for the final models. We performed all statistical analyses with the SPSS software (version 24.0, 
IBM, Armonk, NY, USA). We used GraphPad Prism software, version 8, https ://www.graph pad.com to draw 
the figures.
Results
Blood samples available for analysis included 111 samples collected at ICU admission [median (IQR) delay from 
collapse to admission sample was 200 (160–230) min], 111 samples collected at 24 h, 109 samples collected at 
48 h and 106 samples collected at 72 h. Thirty days after cardiac arrest, 36 patients were dead and 76 were alive. 
The most frequent cause of death was hypoxic ischaemic encephalopathy (32 cases). Six months after cardiac 
arrest 53 patients had CPC class 1 (good cerebral performance), twenty patients had class 2 (moderate cerebral 
disability), two patients had class 3 (severe cerebral disability), none had class 4 (vegetative state) and 37 had 
class 5 (death). Median (interquartile range, IQR) age in forty control patients was 62 (53–69) years and 73% of 
them were male. The baseline characteristics of the study population are presented in Table 1.
In the study population the median (IQR) FGF 21 concentration at ICU admission was 0.79 (0.37–1.6) ng/ml 
and the peak value was 1.2 (0.46–2.5) ng/ml at 48 h. Compared to the ICU admission values, the concentrations 
in control patients’ samples, 0.25 (0.094–0.91) ng/ml, were significantly lower (P < 0.001). The ICU admission 
FGF 21 concentration was higher in patients with poor neurological outcome [1.1 (0.50–2.3) ng/ml] compared to 
those with a good neurological outcome [0.66 (0.29–1.5) ng/ml, (P = 0.04)]. Linear correlations between admis-
sion FGF 21 concentration and patient age, APACHE II score, time from collapse to ROSC or time from collapse 
to sampling were not observed (supplementary Figs. 1–4). FGF 21 concentrations at the studied timepoints are 
presented in Table 1 and Fig. 1.
FGF 21 and oxygen. No significant correlation existed between highest  PaO2 value during the first 48 h of 
ICU stay and FGF 21 at 48 h after cardiac arrest (Fig. 2, panel A) or between FGF 21 at 24 h or 48 h and mean 
 PaO2 value of the preceding 24-h period (Fig. 2, panel B and C). The distribution of patients with poor and good 
outcome were comparable over all these scatterplots (Fig. 2).
In the first linear model analysis with REML estimation with FGF 21 concentration as dependent variable, a 
significant fixed effect of sampling timepoint was found but no effect of  PaO2 intervention group or the interac-
tion of time by intervention group on FGF 21 concentration (Table 2).
FGF 21 and neurological outcome. In the second linear model analysis with REML estimation with 
FGF 21 concentration as dependent variable, there was an effect of sampling timepoint (meaning that FGF 21 
Table 1.  Characteristics of the study patients (N = 112). Continuous variables: median (IQR), Mann Whitney 
U test; categorical variables: percentage of the whole, Fisher’s Exact test. Good outcome, 6-month Cerebral 
Performance Categories (CPC) 1–2; Poor outcome, 6-month CPC 3–5. *Difference between groups is 




N = 39 P-value
Missing data
Good/poor outcome
Age (years) 58 (51–66) 66 (58–75)  < 0.01* 0/0
Sex (male) 84% 80% 0.61 0/0
BMI (kg/m2) 26 (24–29) 26 (23–29) 0.86 0/2
Smoker (yes) 33% 41% 0.50 6/7
Bystander initiated resuscitation (yes) 90% 69%  < 0.01* 0/0
Time to first unit (min) 7.0 (6.0–9.0) 7.0 (5.0–10) 0.91 0/0
Time to  ROSCa (min) 17 (15–22) 25 (22–32)  < 0.001* 0/0
APACHE II (point) 27 (24–29) 31 (26–35)  < 0.01* 0/0
PaO2 group (high) 47% 54% 0.55 0/0
48-h highest  PaO2 (kPa) 27 (21–32) 29 (22–31) 0.64 0/0
Time from ICU admission to highest  PaO2 (h) 2.9 (1.9–8.0) 3.7 (1.7–10) 0.60 0/0
NSE 48 h (ng/ml) 17 (13–25) 49 (25–130)  < 0.001* 0/3
FGF 21 (ng/ml)
Admission 0.66 (0.29–1.5) 1.1 (0.50–2.3) 0.04* 1/0
 24 h 0.92 (0.40–1.8) 0.84 (0.53–1.7) 0.87 0/1
 48 h 1.2 (0.46–2.3) 1.4 (0.43–2.9) 0.46 0/3
 72 h 0.57 (0.19–1.8) 1.2 (0.40–2.8) 0.03* 1/5
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Figure 1.  Concentrations of FGF 21 in controls (N = 40) and outcome groups of study patients. Median with 
interquartile range (box) and 10–90th percentile (whiskers) are presented. Note the logarithmic scale. Good 
outcome (N = 73), 6-month Cerebral Performance Categories (CPC) 1–2; Poor outcome (N = 39), 6-month CPC 
3–5. *Difference between the outcome groups is statistically significant at the P < 0.05 level (Mann Whitney U 
test not adjusted for multiple comparisons).
Figure 2.  Concentrations of FGF 21 in relation to  PaO2. (A) highest arterial blood  PaO2 value measured during 
the first 48 h of ICU stay and FGF 21 concentration measured at 48 h. (B) time-weighted mean arterial blood 
 PaO2 from admission to 24 h and FGF 21 concentration measured at 24 h. (C) time-weighted mean arterial 
blood  PaO2 from 24 to 48 h and FGF 21 concentration measured at 48 h. Black circles, poor outcome; grey 
squares, good outcome.
Table 2.  Effect of timepoint and  PaO2 group. PaO2 group, intervention groups targeting normoxia  (PaO2 
10–15 kPa) or moderate hyperoxia  (PaO2 20–25 kPa). *Statistically significant at the P < 0.05 level.
Fixed effects on FGF 21 concentration (n = 112) df F P-value
Timepoint 3 3.9 0.01*
PaO2 group 1 0.09 0.77
Timepoint × PaO2 group 3 1.4 0.25
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concentrations were significantly different between timepoints) and of poor neurological outcome (meaning 
that FGF 21 concentrations were significantly different between outcome groups) and an interaction of sam-
pling timepoint with poor neurological outcome (meaning that the dynamics of FGF 21 concentration were 
significantly different between outcome groups) (Table 3). Pairwise comparison of estimated marginal means at 
different timepoints indicated a significant increase between 24 and 48 h (mean difference 0.83 ng/ml, 95% CI 
0.42–1.2 ng/ml, P < 0.001, Table 3). The estimated marginal means were higher in the poor outcome group (mean 
difference 1.2 ng/ml, 95% CI 0.24–2.2 ng/ml, P = 0.01, Table 3). Pairwise comparisons of the means defined by 
sampling timepoint by outcome group interaction, indicated a statistically significant difference at the P < 0.0125 
level at 72 h timepoint (mean difference 2.5 ng/ml, 95% CI 0.62–4.4 ng/ml, P < 0.01, Table 3).
In a logistic regression model adjusting for relevant confounding variables, average FGF 21 concentration 
during the first 72 h after cardiac arrest was independently associated with poor 6-month neurological outcome 
(CPC 3–5) (Table 4). The results were similar when the logistic regression model was replicated for predicting 
any 6-month neurological status worse than “good cerebral performance” (i.e. CPC 2–5) (Table 5).
Discussion
The main finding of this study is that serum FGF 21 levels were significantly elevated after successful resuscita-
tion in ICU-treated OHCA patients with shockable initial rhythm. Furthermore, the temporal pattern of FGF 21 
concentration during the first 72 h was different in patients with poor and good 6-month neurological outcome. 
We found no association between arterial blood oxygen partial pressures  (PaO2) and the FGF 21 concentrations 
in patients after cardiac arrest.
Table 3.  Effect of timepoint and outcome. Good outcome, 6-month Cerebral Performance Categories (CPC) 
1–2; Poor outcome, 6-month CPC 3–5; df, numerator degrees of freedom; CI, confidence interval. *Statistically 
significant at the P < 0.05 level (Fixed effects and interactions). **Statistically significant at the P < 0.0125 level 
(four pairwise comparisons of interactions).
Fixed effects on FGF 21 concentration (n = 112) df F P-value
Timepoint 3 5.6  < 0.01*
Poor outcome 1 6.1 0.01*
Timepoint × Poor outcome 3 3.0 0.03*
Pairwise comparisons Mean difference 95% CI P-value
Timepoint
 24 h–admission − 0.12 − 0.81–0.58 0.74
 48 h–24 h 0.83 0.42–1.2  < 0.001*
 72 h–48 h − 0.07 − 0.92–0.79 0.88
Poor outcome
 Poor–good outcome 1.2 0.24–2.2 0.01*
Timepoint × Poor outcome
 Admission
 Poor–good outcome 0.68 − 0.58–1.9 0.29
 24 h
 Poor–good outcome 0.36 − 0.61–1.3 0.46
 48 h
 Poor–good outcome 1.4 0.002–2.8 0.05
 72 h
 Poor–good outcome 2.5 0.62–4.4  < 0.01**
Table 4.  Logistic regression model for predicting 6-month poor neurological outcome (CPC 3–5). Good 
outcome, 6-month Cerebral Performance Categories (CPC) 1–2 (neurological condition ranging from “good 
cerebral performance” to “moderate cerebral disability”); Poor outcome, 6-month CPC 3–5 (neurological 
condition ranging from “severe cerebral disability” to “death”); OR, odds ratio; CI, confidence interval. 
*Statistically significant at the P < 0.05 level.
OR 95% CI P-value
Age (year) 1.09 1.01–1.17 0.03*
Bystander initiated resuscitation (no) 11.5 1.99–66.5  < 0.01*
Delay to ROSC (min) 1.15 1.04–1.26  < 0.01*
APACHE II (excluding age, point) 0.99 0.84–1.18 0.91
NSE 48 h (ng/ml) 1.11 1.05–1.19  < 0.01*
FGF 21 mean concentration admission to 72 h (ng/ml) 1.60 1.10–2.32 0.01*
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The ischaemia–reperfusion injury associated with cardiac arrest is often followed by an inflammatory reaction 
resembling septic  shock22, which may lead to multiple organ failure and death in cardiac arrest patients. In our 
patient cohort we observed elevated FGF 21 levels on ICU admission and an increase between 24 and 48 h time-
points. Interestingly, FGF 21 has been shown to play an anti-inflammatory role in  sepsis23 and hypoxia-induced 
pulmonary  hypertension24 and to protect  myocardium25 and  neurons26 in oxidative stress. Therefore, increasing 
FGF 21 levels can be interpreted to reflect a protective response to severe perturbations in oxidative metabolism.
Our findings are in line with previous data reporting elevated FGF 21 levels in general population of critical 
care  patients13. The emerging role of FGF 21 as a marker of mitochondrial  dysfunction27 combined with reports 
of elevated FGF 21 predicting cardiovascular  events28–30 make cardiac arrest an especially interesting condi-
tion for studying FGF 21 due to the extreme ischaemia–reperfusion event of circulatory standstill followed by 
resuscitation.
Transcription of FGF 21 is regulated by multiple  pathways31. Disturbance of mitochondrial function leads 
to upregulation of FGF 21 transcription by  ATF432, which is a central player in the integrated stress response 
signaling  network13,33. Lactate induces FGF 21 expression in a p38-MAPK dependent  manner34 and activation 
of glucocorticoid receptors increases FGF 21  expression35. Expression of mRNA in tissues and systemic FGF 21 
protein levels change rapidly in response to stressful stimuli. In liver transplants, a robust increase in the expres-
sion of FGF 21 in hepatocytes has been reported with peak systemic concentrations in the recipient as early as 
2 h after return of hepatic blood  flow36. In cardiac surgery and ST-elevation myocardial infarction, peak systemic 
concentrations of FGF 21 were reached 6 h after the  insult37,38. After a short stressful insult such as cardiac surgery 
or liver transplantation, systemic FGF 21 returns to basal level in a few  days36,37, whereas FGF 21 levels in ICU 
patients remain elevated during the length of the ICU  stay13.
Based on these data, it is plausible that the peak systemic concentrations of FGF 21 observed at 48 h in the 
current study are a result of induced transcription in the liver and other tissues in response to hypoxia-reper-
fusion injury associated with the cardiac arrest. The difference in admission values of FGF 21 between outcome 
groups (Table 1, Fig. 1) suggests faster elevation in the poor outcome group, although it may also partly reflect 
the cardiovascular risk factors preceding the cardiac  arrest28–30. The association of higher FGF 21 concentrations 
during the first 72 h with poor 6-month outcome (Tables 3, 4, 5) suggest that the stressful process leading to 
FGF 21 expression fails to resolve in the poor outcome group. In line with this, a downward trend in the median 
FGF 21 concentration between 48 and 72 h can be seen in the good but not in the poor outcome group (Fig. 1).
Therapeutic hypothermia may have an impact on FGF 21  expression38. However, admission samples collected 
already before cooling had increased FGF 21 levels (Table 1, Fig. 1) and although part of the observed dynam-
ics of FGF 21 after cardiac arrest may be associated with hypothermia, this cannot explain the differences seen 
between outcome groups (Tables 3, 4, 5) since all study patients received therapeutic hypothermia.
Global tissue hypoxia is considered a central pathophysiological trigger for the post cardiac arrest  syndrome39. 
However, after reperfusion of the organs, excess oxygen can also be detrimental. In experimental conditions 
hyperoxemia during post-resuscitation period has been reported to exacerbate reperfusion  injury16,17, and ret-
rospective studies of clinical data have suggested that even short exposure to hyperoxia may be associated with 
mortality in cardiac arrest  patients40,41. However, our group has been unable to replicate this result in a prospec-
tive observational  study42 and a large registry  study43. If this association would hold true, mitochondrial injury 
induced by increased reactive oxygen species production stimulated by hyperoxia would provide a plausible 
mechanistic explanation. In the current study we found no association between either highest measured  PaO2 
value or preceding 24-h mean  PaO2 values and FGF 21 concentration as a surrogate marker for mitochondrial 
stress (Fig. 2).
As discussed above, FGF 21 appears to protect against damaging inflammation, reperfusion injury and 
oxidative stress when administered to cell cultures or laboratory  animals23–26. This protective measure can be 
overwhelmed, and FGF 21 has been shown to predict renal injury after coronary  angiography44, liver failure in 
critically ill patients with  cirrhosis45, and poor outcome in patients with  sepsis46,47. To the best of our knowledge, 
there are no previous animal or human studies assessing the FGF 21 response following cardiac arrest or its 
association with post-resuscitation neurological outcome. In the current study, higher serum FGF 21 concen-
trations during post-resuscitation care were associated with 6-month poor neurological outcome (Tables 3, 4, 
5). The magnitude of the FGF 21 response appears to reflect the severity of the systemic hypoxia-reperfusion 
injury in cardiac arrest patients, although the large variation in FGF 21 concentrations does not allow its use for 
prognostication on single patient level.
Table 5.  Logistic regression model for predicting 6-month Cerebral Performance Categories 2–5 (neurological 
condition not classified as CPC 1 “good cerebral performance”). OR, odds ratio; CI, confidence interval. 
*Statistically significant at the P < 0.05 level.
OR 95% CI P-value
Age (year) 1.09 1.03–1.16  < 0.01*
Bystander initiated resuscitation (no) 2.31 0.51–10.5 0.28
Delay to ROSC (min) 1.16 1.06–1.26  < 0.01*
APACHE II (excluding age, point) 1.01 0.90–1.14 0.86
NSE 48 h (ng/ml) 1.07 1.01–1.13 0.02*
FGF 21 mean concentration admission to 72 h (ng/ml) 1.50 1.11–2.02  < 0.01*
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Strengths and limitations of the study
This was a multicenter study conducted in a government-funded healthcare system with good research infra-
structure. No patient was lost to follow-up and sera were available for all four studied timepoints. The assessor 
of outcome was blinded and FGF 21 measurements were performed blinded to clinical information. Our study 
has also limitations. First, the patient population consisted of only OHCA patients with VF/VT as the initial 
cardiac rhythm and, thus, the generalizability of our findings regarding all cardiac arrest patients is limited. 
Second, the median time for the first unit to reach the patient was only 7 min, which is not the case in less urban 
patient cohorts. Third, we had no data on prehospital  PaO2 or on the pre-arrest FGF 21 levels. Since elevated 
FGF 21 levels are associated with increased risk of cardiovascular events, there is a possibility that elevated FGF 
21 levels after cardiac arrest partly reflect the pre-arrest chronic morbidity of the cardiovascular system and not 
only conditions associated with the acute event. Finally, this was a rather small pilot study with only 39 poor 
outcome events, limiting the statistical power of the study.
Conclusions
Our results suggest a role for FGF 21 in the hypoxia-reperfusion injury following cardiac arrest. Critically ill 
patients resuscitated after OHCA have elevated FGF 21 concentrations on ICU admission and the temporal pat-
tern and magnitude of FGF 21 response seem to differ according to 6-month neurological outcome. The FGF 21 
response is not affected by moderate hyperoxia during ICU care. The large variation on FGF 21 concentrations 
discourage its clinical use for outcome prediction in cardiac arrest.
Data availability
The dataset analyzed during the current study includes sensitive patient information. Legal restrictions prohibit 
us from making the data publicly available. Data excluding patient identifying information are available from 
the corresponding author on reasonable request.
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